RetinalGeniX Technologies, Inc. is a publicly held emerging medical device company focused on preventing blindness through a cost-effective Mass Retinal Screening Device and a Patient Real-Time Home Monitoring Imaging & Physician Alert System.
The Mass Retinal Screening device provides retinal imaging that captures a 200° FOV without pupil dilation and detects the earliest stages of diabetic retinopathy to prevent blindness. This device requires submission to the FDA’s 510(k) approval process.
RetinalGeniX’s second product is RetinalCamTM, the first in-home, self-monitoring device providing real-time ocular and retinal imaging and streaming video to the physician. The technology enables high-risk individuals to send their physician digitized retinal images and stream video easily from their homes. This second device does not require submission to the FDA’s 510(k) approval.
Diabetes is a growing epidemic in the United States and abroad.
|US:||CDC National Diabetes Statistics Report, 2020|
|34.2 M Americans have diabetes / 10.5% of the population
(26.8M diagnosed, 7.3M undiagnosed)
|88 M American adult have pre-diabetes|
|Global:||2019 Report: International Diabetes Foundation|
|2019 – 463 M adults had diabetes|
|2045 – 700 M adults projected to have diabetes|
Being overweight or obese greatly increases your risk of developing Type 2 diabetes.
Recent research suggests that obese people are up to 80 times more likely to develop type 2 diabetes than those with a BMI of less than 22. Jan 15, 2019, www.diabetes.co.uk
Diabetic retinopathy is a degenerative disease of the retina, which is the layer of receptors in the eyes that receive light and pass the signals to the brain via the optic nerve. As the retina degenerates patients experience loss of vision due to bleeding, retinal detachment, and other factors.
- Left untreated diabetic retinopathy can lead to permanent blindness.
- Detected early and treated, retinopathy and maculopathy can be stopped so that vision can be maintained.